Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,356 recalls, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 20262025202420232022 All years
Cause Sterility / contaminationNitrosamine impurityChemical / undeclaredParticulate / foreign matterLabeling / mix-upcGMP deviationMicrobial contamination All causes
Class II · Moderate risk

Amlodipine Besylate and Benazepril HCl Capsules

CGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices.

Terminated cGMP deviation Mylan Pharmaceuticals Inc. NDC 0378-6895-01 D-66403-002
Class II · Moderate risk

Amlodipine Besylate Tablets

CGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices.

Terminated cGMP deviation Mylan Pharmaceuticals Inc. NDC 0378-5208-77 D-66403-001
Class II · Moderate risk

Acetaminophen Tablets

CGMP Deviations: The recalled acetaminophen tablet lot was not manufactured under current good manufacturing practices as noted by a recent inspection of the manufacturing firm.

Terminated cGMP deviation Marlex Pharmaceuticals, Inc. NDC 10135-152-01 D-1064-2013
Class III · Low risk

Disulfiram Tablets USP 250 mg

CGMP Deviation; cotton coil is missing in some packaged bottles

Terminated cGMP deviation Teva Pharmaceuticals USA, Inc. NDC 0093-5035-01 D-578-2013
Class II · Moderate risk

Benjamins Infants Gripe Mixture

CGMP Deviations: this product is being recalled because an FDA inspection revealed that it was not manufactured under current good manufacturing practices.

Terminated cGMP deviation Carib Import & Export, Inc. D-307-2013
Class II · Moderate risk

Medi-bolic Booster Injectable

CGMP Deviations: Pharmaceutical for injection was not manufactured according to Good Manufacturing Procedures.

Terminated cGMP deviation RX South LLC DBA RX3 Pharmacy D-191-2013
Class II · Moderate risk

ABILIFY (aripiprazole)

CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.

Terminated cGMP deviation Bristol Myers Squibb Manufacturing Company NDC 59148-011-35 D-181-2013
Class III · Low risk

Lemon Hand Sanitizing Wipes

CGMP Deviations: The products were manufactured with raw material which contain unknown particles believed to be water and dirt.

Terminated cGMP deviation ITW Dymon D-056-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1328-01 D-085-2013
Class II · Moderate risk

Thyro-Tab 0.300 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-084-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1331-01 D-083-2013
Class II · Moderate risk

Thyro-Tab 0.137 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-082-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1324-01 D-081-2013
Class II · Moderate risk

Thyro-Tab 0.125 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-080-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1330-01 D-079-2013
Class II · Moderate risk

Thyro-Tab 0.112 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-078-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1329-01 D-077-2013
Class II · Moderate risk

Thyro-Tab 0.088 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-076-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1321-01 D-075-2013
Class II · Moderate risk

Thyro-Tab 0.050 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-074-2013

Recalls by year